Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: A Promising Medication for Chronic Obstructive Pulmonary Disease?

References

• Vogelmeier CF, Criner GJ, Martínez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD Executive Summary. Arch Bronconeumol. 2017;53:128–149. doi:10.1016/j.arbres.2017.02.001.
   PubMed Web of Science ®Google Scholar
• Vos T, Allen C, Arora M, Barber RM, Bhutta ZA, Brown A, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1545–1602. doi:10.1016/S0140-6736(16)31678-6. PMID:27733282.
   PubMed Web of Science ®Google Scholar
• Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: Role of comorbidities. Eur Respir J. 2006;28:1245–1257. doi:10.1183/09031936.00133805. PMID:17138679.
   PubMed Web of Science ®Google Scholar
• Rabinovich RA, MacNee W. Chronic obstructive pulmonary disease and its comorbidities. Br J Hosp Med. 2011;72:137–145. doi:10.12968/hmed.2011.72.3.137.
   PubMed Web of Science ®Google Scholar
• Studdy PR, Lapworth R, Bird R. Angiotensin-converting enzyme and its clinical significance-a review. J Clin Pathol. 1983;36:938–947. doi:10.1136/jcp.36.8.938. PMID:6308066.
   PubMed Web of Science ®Google Scholar
• Kakar SS, Sellers JC, Devor DC, Musgrove LC, Neill JD. Angiotensin II type-1 receptor subtype cDNAs: differential tissue expression and hormonal regulation. Biochem Biophys Res Commun. 1992;183:1090–1096. doi:10.1016/S0006-291X(05)80302-X. PMID:1567388.
   PubMed Web of Science ®Google Scholar
• Shrikrishna D, Astin R, Kemp PR, Hopkinson NS. Renin–angiotensin system blockade: a novel therapeutic approach in chronic obstructive pulmonary disease. Clin Sci. 2012;123:487–498. doi:10.1042/CS20120081. PMID:22757959.
   PubMed Web of Science ®Google Scholar
• Bullock GR, Steyaert I, Bilbe G, Carey RM, Kips J, De Paepe B, Pauwels R, Praet M, Siragy HM, de Gasparo M. Distribution of type-1 and type-2 angiotensin receptors in the normal human lung and in lungs from patients with chronic obstructive pulmonary disease. Histochem Cell Biol. 2001;115:117–124. doi:10.1007/s004180000235. PMID:11444146.
   PubMed Web of Science ®Google Scholar
• Passos-Silva DG, Brandan E, Santos RA. Angiotensins as therapeutic targets beyond heart disease. Trends Pharmacol Sci. 2015;36:310–320. doi:10.1016/j.tips.2015.03.001. PMID:25847571.
   PubMed Web of Science ®Google Scholar
• Bader M. Tissue renin–angiotensin–aldosterone systems: targets for pharmacological therapy. Annu Rev Pharmacol Toxicol. 2010;50:439–465. doi:10.1146/annurev.pharmtox.010909.105610. PMID:20055710.
   PubMed Web of Science ®Google Scholar
• Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, Heringer-Walther S, Pinheiro SV, Lopes MT, Bader M, et al. Angiotensin-(1–7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA. 2003;100:8258–8263. doi:10.1073/pnas.1432869100. PMID:12829792.
   PubMed Web of Science ®Google Scholar
• Gironacci MM, Adamo HP, Corradi G, Santos RA, Ortiz P, Carretero OA. Angiotensin (1–7) induces MAS receptor internalization. Hypertension. 2011;58:176–181. doi:10.1161/HYPERTENSIONAHA.111.173344. PMID:21670420.
   PubMedGoogle Scholar
• Maron BA, Leopold JA. Emerging concepts in the molecular basis of pulmonary arterial hypertension part II: Neurohormonal signaling contributes to the pulmonary vascular and right ventricular pathophenotype of pulmonary arterial hypertension. Circulation. 2015;131:2079–2091. doi:10.1161/CIRCULATIONAHA.114.006980. PMID:26056345.
   PubMed Web of Science ®Google Scholar
• Der Sarkissian S, Grobe JL, Yuan L, Narielwala DR, Walter GA, Katovich MJ, Raizada MK. Cardiac overexpression of angiotensin converting enzyme 2 protects the heart from ischemia-induced pathophysiology. Hypertension. 2008;51:712–718. doi:10.1161/HYPERTENSIONAHA.107.100693. PMID:18250366.
   PubMed Web of Science ®Google Scholar
• Grobe JL, Mecca AP, Lingis M, Shenoy V, Bolton TA, Machado JM, Speth RC, Raizada MK, Katovich MJ. Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1–7). Am J Physiol Heart Circ Physiol. 2007;292:H736–H742. doi:10.1152/ajpheart.00937.2006. PMID:17098828.
   PubMed Web of Science ®Google Scholar
• Santos RA, Ferreira AJ, Simões E Silva AC. Recent advances in the angiotensin-converting enzyme 2 angiotensin (1–7)-Mas axis. Exp Physiol. 2008;93:519–527. doi:10.1113/expphysiol.2008.042002. PMID:18310257.
   PubMed Web of Science ®Google Scholar
• Cole-Jeffrey CT, Liu M, Katovich MJ. ACE2 and Microbiota: Emerging Targets for Cardiopulmonary Disease Therapy. J Cardiovasc Pharmacol. 2015;66:540–550. doi:10.1097/FJC.0000000000000307. PMID:26322922.
   PubMed Web of Science ®Google Scholar
• Tallant EA, Ferrario CM, Gallagher PE. Angiotensin-(1–7) inhibits growth of cardiac myocytes through activation of the mas receptor. Am J Physiol Heart Circ Physiol. 2005;289:H1560–H1566. doi:10.1152/ajpheart.00941.2004. PMID:15951342.
   PubMed Web of Science ®Google Scholar
• Shenoy V, Ferreira AJ, Qi Y, Fraga-Silva RA, Díez-Freire C, Dooies A, Jun JY, Sriramula S, Mariappan N, Pourang D, et al. The angiotensin-converting enzyme 2/angiogenesis-(1–7)/mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med. 2010;182:1065–1072. doi:10.1164/rccm.200912-1840OC. PMID:20581171.
   PubMed Web of Science ®Google Scholar
• Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450–454. doi:10.1038/nature02145. PMID:14647384.
   PubMed Web of Science ®Google Scholar
• Zou Z, Yan Y, Shu Y, Gao R, Sun Y, Li X, Ju X, Liang Z, Liu Q, Zhao Y, et al. Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infections. Nat Commun. 2014;5:3594. doi:10.1038/ncomms4594. PMID:24800825.
   PubMed Web of Science ®Google Scholar
• Liu X, Yang N, Tang J, Liu S, Luo D, Duan Q, Wang X. Downregulation of ACE 2 by the neuraminidase protein of influenza A (H1N1) virus. Virus Res. 2014;185:64–71. doi:10.1016/j.virusres.2014.03.010. PMID:24662240.
   PubMed Web of Science ®Google Scholar
• Marshall RP. The pulmonary renin-angiotensin system. Curr Pharm Des 2003;9:715–722. doi:10.2174/1381612033455431. PMID:12570789.
   PubMed Web of Science ®Google Scholar
• Chao J, Donham P, van Rooijen N, Wood JG, Gonzalez NC. Monocyte chemoattractant protein-1 released from alveolar macrophages mediates the systemic inflammation of acute alveolar hypoxia. Am J Respir Cell Mol Biol. 2011;45:53–61. doi:10.1165/rcmb.2010-0264OC. PMID:20813992.
   PubMed Web of Science ®Google Scholar
• Kaparianos A, Argyropoulou E. Local renin-angiotensin II systems, angiotensin-converting enzyme and its homologue ACE2: their potential role in the pathogenesis of chronic obstructive pulmonary diseases, pulmonary hypertension and acute respiratory distress syndrome. Curr Med Chem. 2011;18:3506–3515. doi:10.2174/092986711796642562. PMID:21756232.
   PubMed Web of Science ®Google Scholar
• Benigni A, Cassis P, Remuzzi G. Angiotensin II revisited: new roles in inflammation, immunology and aging. EMBO Mol Med. 2010;2:247–257. doi:10.1002/emmm.201000080. PMID:20597104.
   PubMed Web of Science ®Google Scholar
• Rahman I, Adcock IM. Oxidative stress and redox regulation of lung inflammation in COPD. Eur Respir J. 2006;28:219–242. doi:10.1183/09031936.06.00053805. PMID:16816350.
   PubMed Web of Science ®Google Scholar
• Chilosi M, Poletti V, Rossi A. The pathogenesis of COPD and IPF: distinct horns of the same devil? Respir Res. 2012;13:3. doi:10.1186/1465-9921-13-3. PMID:22235752.
   PubMed Web of Science ®Google Scholar
• Jankowich MD, Rounds SIS. Combined pulmonary fibrosis and emphysema syndrome: a review. Chest. 2012;141:222–231. doi:10.1378/chest.11-1062. PMID:22215830.
   PubMed Web of Science ®Google Scholar
• Uhal BD, Li X, Piasecki CC, Molina-Molina M. Angiotensin signalling in pulmonary fibrosis. Int J Biochem Cell Biol. 2012;44:465–468. doi:10.1016/j.biocel.2011.11.019. PMID:22155301.
   PubMed Web of Science ®Google Scholar
• Kϕnigshoff M, Wilhelm A, Jahn A, Sedding D, Amarie OA, Eul B, Seeger W, Fink L, Gόnther A, Eickelberg O, Rose F. The angiotensin II receptor 2 is expressed and mediates angiotensin II signaling in lung fibrosis. Am. J. Respir. Cell Mol. Biol. 2007;37:640–650. doi:10.1165/rcmb.2006-0379TR. PMID:17630322.
   PubMed Web of Science ®Google Scholar
• Marshall RP, McAnulty RJ, Laurent GJ. Angiotensin II is mitogenic for human lung fibroblasts via activation of the type 1 receptor. Am. J. Respir. Crit. Care Med. 2000;161:1999–904. doi:10.1164/ajrccm.161.6.9907004. PMID:10852780.
   PubMed Web of Science ®Google Scholar
• Uhal BD, Kim JK, Li X, Molina-Molina M. Angiotensin-TGF-beta 1 crosstalk in human idiopathic pulmonary fibrosis: autocrine mechanisms in myofibroblasts and macrophages. Curr. Pharm. Des. 2007;13:1247–1256. doi:10.2174/138161207780618885. PMID:17504233.
   PubMed Web of Science ®Google Scholar
• Abdul-Hafez A, Shu R, Uhal BD. JunD and HIF-1α mediate transcriptional activation of angiotensinogen by TGF-β1 in human lung fibroblasts. FASEB J. 2009;23:1655–1662. doi:10.1096/fj.08-114611. PMID:19211927.
   PubMed Web of Science ®Google Scholar
• Hussain A, Wyatt AW, Wang K, Bhandaru M, Biswas R, Avram D, Föller M, Rexhepaj R, Friedrich B, Ullrich S, et al. SGK1-dependent upregulation of connective tissue growth factor by angiotensin II. Kidney Blood Press. Res. 2008;31:80–86. doi:10.1159/000119703. PMID:18319604.
   PubMed Web of Science ®Google Scholar
• Renzoni EA, D, Abraham J, Howat S, Shi-Wen X, Sestini P, Bou-Charios G, Wells AU, Veeraraghavan S, Nicholson AG, Denton CP, et al. Gene expression profiling reveals novel TGFβ targets in adult lung fibroblasts. Respiratory Research. 2004;5:24. doi:10.1186/1465-9921-5-24. PMID:15571627.
   PubMed Web of Science ®Google Scholar
• Meng Y, Meng Y, Li X, Cai SX, Tong WC, Cheng YX. Perindopril and losartan attenuate bleomycin A5-induced pulmonary fibrosis in rats. Nan Fang Yi Ke Da Xue Xue Bao. 2008;28:919–924. PMID:18583228.
   PubMedGoogle Scholar
• Otsuka M, Takahashi H, Shiratori M, Chiba H, Abe S. Reduction of bleomycin induced lung fibrosis by candesartan cilexetil, an angiotensin II type 1 receptor antagonist. Thorax. 2004;59:31–38. doi:10.1136/thx.2003.000893. PMID:14694243.
   PubMed Web of Science ®Google Scholar
• Molteni A, Wolfe LF, Ward WF, Tsao CH, Molteni LB, Veno P, Fish BL, Taylor JM, Quintanilla N, Herndon B, et al. Effect of an angiotensin II receptor blocker and two angiotensin converting enzyme inhibitors on transforming growth factor-beta (TGF-beta) and alpha actomyosin (alpha SMA), important mediators of radiation-induced pneumopathy and lung fibrosis. Curr. Pharm. Des. 2007;13:1307–1316. doi:10.2174/138161207780618777. PMID:17506716.
   PubMed Web of Science ®Google Scholar
• Chen N, Li JJ, Xue XD. Effect of losartan on lung fibrosis in neonatal rats with hyperoxia-induced chronic lung disease. Zhongguo Dang Dai Er Ke Za Zhi. 2007;9:591–594. PMID:18082049.
   PubMedGoogle Scholar
• Podowski M, Calvi C, Metzger S, Misono K, Poonyagariyagorn H, Lopez-Mercado A, Ku T, Lauer T, McGrath-Morrow S, Berger A, et al. Angiotensin receptor blockade attenuates cigarette smoke-induced lung injury and rescues lung architecture in mice. J Clin Invest. 2012;122:229–240. doi:10.1172/JCI46215. PMID:22182843.
   PubMed Web of Science ®Google Scholar
• Uhal BD, Dang M, Dang V, Llatos R, Cano E, Abdul-Hafez A, Markey J, Piasecki CC, Molina-Molina M. Cell cycle dependence of ACE-2 explains downregulation in idiopathic pulmonary fibrosis. Eur Respir J. 2013;42:198–210. doi:10.1183/09031936.00015612. PMID:23100504.
   PubMedGoogle Scholar
• Li X, Molina-Molina M, Abdul-Hafez A, Uhal V, Xaubet A, Uhal BD. Angiotensin converting enzyme-2 is protective but downregulated in human and experimental lung fibrosis. Am J Physiol Lung Cell Mol Physiol. 2008;295:L178–L185. doi:10.1152/ajplung.00009.2008. PMID:18441099.
   PubMed Web of Science ®Google Scholar
• Wu H, Li Y, Wang Y, Xu D, Li C, Liu M, Sun X, Li Z. Tanshinone IIA attenuates bleomycin-induced pulmonary fibrosis via modulating angiotensin-converting enzyme 2/ angiotensin-(1-7) axis in rats. Int J Med Sci. 2014;11:578–586. doi:10.7150/ijms.8365. PMID:24782646.
   PubMed Web of Science ®Google Scholar
• Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37:67–119.
   PubMed Web of Science ®Google Scholar
• Seeger W, Adir Y, Barberà JA, Champion H, Coghlan JG, Cottin V, De Marco T, Galiè N, Ghio S, Gibbs S, et al. Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol. 2013;62(25 Suppl):D109–D116. doi:10.1016/j.jacc.2013.10.036. PMID:24355635.
   PubMed Web of Science ®Google Scholar
• Shino MY, Lynch JP 3rd, Saggar R, Abtin F, Belperio JA, Saggar R. Pulmonary hypertension complicating interstitial lung disease and COPD. Semin Respir Crit Care Med. 2013;34:600–619. doi:10.1055/s-0033-1356548. PMID:24037628.
   PubMed Web of Science ®Google Scholar
• Maron BA, Leopold JA. The role of the renin-angiotensin-aldosterone system in the pathobiology of pulmonary arterial hypertension. Pulm Circ. 2014;4:200–210. doi:10.1086/675984. PMID:25006439.
   PubMed Web of Science ®Google Scholar
• Maron BA, Zhang YY, White K, Chan SY, Handy DE, Mahoney CE, Loscalzo J, Leopold JA. Aldosterone inactivates the endothelin-B receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension. Circulation. 2012;126:963–974. doi:10.1161/CIRCULATIONAHA.112.094722. PMID:22787113.
   PubMed Web of Science ®Google Scholar
• Maron BA, Opotowsky AR, Landzberg MJ, Loscalzo J, Waxman AB, Leopold JA. Plasma aldosterone levels are elevated in patients with pulmonary arterial hypertension in the absence of left ventricular heart failure: a pilot study. Eur J Heart Fail. 2013;15:277–283. doi:10.1093/eurjhf/hfs173. PMID:23111998.
   PubMed Web of Science ®Google Scholar
• de Man FS, Tu L, Handoko ML, Rain S, Ruiter G, François C, Schalij I, Dorfmüller P, Simonneau G, Fadel E, et al. Dysregulated renin-angiotensin- aldosterone system contributes to pulmonary arterial hypertension. Am J Respir Crit Care Med 2012;186:780–789. doi:10.1164/rccm.201203-0411OC. PMID:22859525.
   PubMed Web of Science ®Google Scholar
• Li G, Liu Y, Zhu Y, Liu A, Xu Y, Li X, Li Z, Su J, Sun L. ACE2 activation confers endothelial protection and attenuates neointimal lesions in prevention of severe pulmonary arterial hypertension in rats. Lung. 2013;191:327–336. doi:10.1007/s00408-013-9470-8. PMID:23652350
   PubMed Web of Science ®Google Scholar
• Agusti AG, Noguera A, Sauleda J, Sala E, Pons J, Busquets X. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J. 2003;21:347–360. doi:10.1183/09031936.03.00405703. PMID:12608452.
   PubMed Web of Science ®Google Scholar
• Man WD, Hopkinson NS, Harraf F, Nikoletou D, Polkey MI, Moxham J. Abdominal muscle and quadriceps strength in chronic obstructive pulmonary disease. Thorax. 2005;60:718–722. doi:10.1136/thx.2005.040709. PMID:15923239.
   PubMed Web of Science ®Google Scholar
• Man WD, Soliman MG, Nikoletou D, Harris ML, Rafferty GF, Mustfa N, Polkey MI, Moxham J. Non-volitional assessment of skeletal muscle strength in patients with chronic obstructive pulmonary disease. Thorax. 2003;58:665–669. doi:10.1136/thorax.58.8.665. PMID:12885979.
   PubMed Web of Science ®Google Scholar
• Gosselink R, Troosters T, Decramer M. Peripheral muscle weakness contributes to exercise limitation in COPD. Am J Respir Crit Care Med. 1996;153:976–980. doi:10.1164/ajrccm.153.3.8630582. PMID:8630582.
   PubMed Web of Science ®Google Scholar
• Shrikrishna D, Hopkinson NS. Chronic obstructive pulmonary disease: consequences beyond the lung. Clin Med. 2012;12:71–74. doi:10.7861/clinmedicine.12-1-71.
   PubMed Web of Science ®Google Scholar
• Decramer M, Gosselink R, Troosters T, Verschueren M, Evers G. Muscle weakness is related to utilization of health care resources in COPD patients. Eur Respir J. 1997;10:417–423. doi:10.1183/09031936.97.10020417. PMID: 9042643.
   PubMed Web of Science ®Google Scholar
• Swallow EB, Reyes D, Hopkinson NS, Man WD, Porcher R, Cetti EJ, Moore AJ, Moxham J, Polkey MI. Quadriceps strength predicts mortality in patients with moderate to severe chronic obstructive pulmonary disease. Thorax. 2007;62:115–120. doi:10.1136/thx.2006.062026. PMID:17090575.
   PubMed Web of Science ®Google Scholar
• Song YH, Li Y, Du J, Mitch WE, Rosenthal N, Delafontaine P. Muscle-specific expression of IGF-1 blocks angiotensin II-induced skeletal muscle wasting. J Clin Invest. 2005;115:451–458. doi:10.1172/JCI22324. PMID:15650772.
   PubMed Web of Science ®Google Scholar
• Acuña MJ, Pessina P, Olguin H, Cabrera D, Vio CP, Bader M, Muñoz-Canoves P, Santos RA, Cabello-Verrugio C, Brandan E. Restoration of muscle strength in dystrophic muscle by angiotensin-1-7 through inhibition of TGF-b signalling. Hum Mol Genet. 2014;23:1237–1249. doi:10.1093/hmg/ddt514. PMID:24163134.
   PubMed Web of Science ®Google Scholar
• Sabharwal R, Cicha MZ, Sinisterra RD, De Sousa FB, Santos RA, Chapleau MW. Chronic oral administration of Ang-(1–7) improves skeletal muscle, autonomic and locomotor phenotypes in muscular dystrophy. Clin Sci. (Lond.) 2014;127:101–109. doi:10.1042/CS20130602. PMID:24502705.
   PubMed Web of Science ®Google Scholar
• Riquelme C, Acuña MJ, Torrejón J, Rebolledo D, Cabrera D, Santos RA. ACE2 is augmented in dystrophic skeletal muscle and plays a role in decreasing associated fibrosis. PLoS ONE. 2014;9:e93449. doi:10.1371/journal.pone.0093449. PMID:24695436.
   PubMed Web of Science ®Google Scholar
• Morales MG, Abrigo J, Meneses C, Cisternas F, Simon F, Cabello-Verrugio C. Expression of the Mas receptor is upregulated in skeletal muscle wasting. Histochem. Cell Biol. 2015;143:131–141. doi:10.1007/s00418-014-1275-1. PMID:25208653.
   PubMed Web of Science ®Google Scholar
• Cisternas F, Morales MG, Meneses C, Simon F, Brandan E, Abrigo J, Vazquez Y, Cabello-Verrugio C. Angiotensin-(1–7) decreases skeletal muscle atrophy induced by angiotensin II through a Mas receptor-dependent mechanism. Clin Sci. 2015;128:307–319. doi:10.1042/CS20140215. PMID:25222828.
   PubMed Web of Science ®Google Scholar
• Morales MG, Abrigo J, Meneses C, Simon F, Cisternas F, Rivera JC, Vazquez Y, Cabello-Verrugio C. The Ang-(1–7)/Mas-1 axis attenuates the expression and signalling of TGF-b1 induced by AngII in mouse skeletal muscle. Clin Sci. 2014;127:251–264. doi:10.1042/CS20130585. PMID:24588264.
   PubMed Web of Science ®Google Scholar
• Baudin B. Angiotensin I-converting enzyme gene polymorphism and drug response. Clin Chem Lab Med. 2000;38:853–856. doi:10.1515/CCLM.2000.123. PMID:11097339.
   PubMed Web of Science ®Google Scholar
• Kanazawa H, Okamoto T, Hirata K, Yoshikawa J. Deletion polymorphisms in the angiotensin converting enzyme gene are associated with pulmonary hypertension evoked by exercise challenge in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;162:1235–1238. doi:10.1164/ajrccm.162.4.9909120. PMID:11029323.
   PubMed Web of Science ®Google Scholar
• Busquets X, MacFarlane NG, Heine-Suner D, Morla M, Torres-Juan L, Iglesias A, Lladó J, Sauleda J, Agustí AG. Angiotensin-converting-enzyme gene polymorphisms, smoking and chronic obstructive pulmonary disease. Int J Chronic Obstruct Pulm Dis. 2007;2:329–334.
   PubMedGoogle Scholar
• Tkacova R, Joppa P. Angiotensin-converting enzyme genotype and C-reactive protein in patients with COPD. Eur Respir J. 2007;29:816–817. doi:10.1183/09031936.00147506. PMID:17400881.
   PubMed Web of Science ®Google Scholar
• Mlak R, Homa-Mlak I, Powrózek T, Mackiewicz B, Michnar M, Krawczyk P, Dziedzic M, Rubinsztajn R, Chazan R, Milanowski J, et al. Impact of I/D polymorphism of ACE gene on risk of development and course of chronic obstructive pulmonary disease. Arch Med Sci. 2016;12:279–287. doi:10.5114/aoms.2015.50757. PMID:27186170.
   PubMed Web of Science ®Google Scholar
• Kang SW, Kim SK, Chung JH, Jung HJ, Kim KI, Kim J, Ban JY. Genetic polymorphism of angiotensin-converting enzyme and chronic obstructive pulmonary Disease risk: An updated meta-analysis. Biomed Res Int. 2016;2016:7636123. Epub 2016 Oct 18. doi:10.1155/2016/7636123. PMID:27830153.
   PubMedGoogle Scholar
• Nong Z, Stassen JM, Moons L, Collen D, Janssens S. Inhibition of tissue angiotensin-converting enzyme with quinapril reduces hypoxic pulmonary hypertension and pulmonary vascular remodeling. Circulation. 1996;94:1941–1947. doi:10.1161/01.CIR.94.8.1941. PMID:8873672.
   PubMed Web of Science ®Google Scholar
• Llorens-Cortes C, Greenberg B, Huang H, Corvol P. Tissular expression and regulation of type 1 angiotensin II receptor subtypes by quantitative reverse transcriptase-polymerase chain reaction analysis. Hypertension. 1994;24:538–548. doi:10.1161/01.HYP.24.5.538. PMID:7525476.
   PubMed Web of Science ®Google Scholar
• Molteni A, Ward WF, Tsao CH, Taylor J, Small W Jr, Brizio- Molteni L, Veno PA. Cytostatic properties of some angiotensin I converting enzyme inhibitors and of angiotensin II type I receptor antagonists. Curr Pharm Des. 2003;9:751–761. doi:10.2174/1381612033455396. PMID:12570792.
   PubMed Web of Science ®Google Scholar
• Wosten-van Asperen RM, Lutter R, Haitsma JJ, Merkus MP, van Woensel JB, van der Loos CM, Florquin S, Lachmann B, Bos AP. ACE mediates ventilator-induced lung injury in rats via angiotensin II but not bradykinin. Eur Respir J. 2008;31:363–371. doi:10.1183/09031936.00060207. PMID:17959639.
   PubMed Web of Science ®Google Scholar
• Suzuki M, Teramoto S, Katayama H, Ohga E, Matsuse T, Ouchi Y. Effects of angiotensin-converting enzyme (ACE) inhibitors on oxygen radical production and generation by murine lungalveolar macrophages. J Asthma. 1999;36:665–670. doi:10.3109/02770909909055418. PMID:10609621.
   PubMed Web of Science ®Google Scholar
• Wang R, Zagariya A, Ibarra-Sunga O, Gidea C, Ang E, Deshmukh S, Chaudhary G, Baraboutis J, Filippatos G, Uhal BD. Angiotensin II induces apoptosis in human and rat alveolar epithelial cells. Am J Physiol. 1999;276:L885–L889. PMID:10330045.
   PubMed Web of Science ®Google Scholar
• Forth R, Montgomery H. ACE in COPD: a therapeutic target? Thorax. 2003;58:556–558. doi:10.1136/thorax.58.7.556. PMID:12832663.
   PubMed Web of Science ®Google Scholar
• Mancini GB, Etminan M, Zhang B, Levesque LE, FitzGerald JM, Brophy JM. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol. 2006;47:2554–2560. doi:10.1016/j.jacc.2006.04.039. PMID:16781387.
   PubMed Web of Science ®Google Scholar
• Mortensen EM, Copeland LA, Pugh MJ, Restrepo MI, de Molina RM, Nakashima B, Anzueto A. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res. 2009;10:45. doi:10.1186/1465-9921-10-45. PMID:19493329.
   PubMed Web of Science ®Google Scholar
• Paulin P, Maritano Furcada J, Ungaro CM, Bendelman G, Waisman GD, Castro HM, Giunta DH, Ferreyro BL. Effect of angiotensin 2 receptor blockers on chronic obstructive lung disease mortality: A retrospective cohort study. Pulm Pharmacol Ther. 2017;44:78–82. doi:10.1016/j.pupt.2017.03.007. PMID:28315489.
   PubMed Web of Science ®Google Scholar
• Petersen H, Sood A, Meek PM, Shen X, Cheng Y, Belinsky SA, Owen CA, Washko G, Pinto-Plata V, Kelly E, et al. Rapid lung function decline in smokers is a risk factor for COPD and is attenuated by angiotensin-converting enzyme inhibitor use. Chest. 2014;145:695–703. doi:10.1378/chest.13-0799. PMID:24008986.
   PubMed Web of Science ®Google Scholar
• Ho TW, Tsai YJ, Ruan SY, Huang CT, Lai F, Yu CJ;HINT Study Group. In-hospital and one-year mortality and their predictors in patients hospitalized for first-ever chronic obstructive pulmonary disease exacerbations: a nationwide population-based study. PLoS One. 2014;9:e114866. doi:10.1371/journal.pone.0114866. PMID:25490399.
   PubMed Web of Science ®Google Scholar
• Di Marco F, Guazzi M, Vicenzi M, Santus P, Cazzola M, Pappalettera M, Castellotti P, Centanni S. Effect of enalapril on exercise cardiopulmonary performance in chronic obstructive pulmonary disease: a pilot study. Pulm Pharmacol Ther. 2010;23:159–164. doi:10.1016/j.pupt.2010.01.004. PMID:20096799.
   PubMed Web of Science ®Google Scholar
• Curtis KJ, Meyrick VM, Mehta B, Haji GS, Li K, Montgomery H, Man WD, Polkey MI, Hopkinson NS. Angiotensin-converting enzyme inhibition as an adjunct to pulmonary rehabilitation in COPD. Am J Respir Crit Care Med. 2016;194:1349–1357. doi:10.1164/rccm.201601-0094OC. PMID:27248440.
   PubMed Web of Science ®Google Scholar
• Robert A. Wise. Efficacy of Losartan in Preventing Progression of COPD [online], 2017. Available from:< https://.gov/ct2/show/NCT00720226>, [accessed 05/11/2017].
   Google Scholar
• Zeng LH, HuYX, Liu L, Zhang M, Cui H. Impact of beta2-agonists, beta-blockers, and their combination on cardiac function in elderly male patients with chronic obstructive pulmonary disease. Clin Interv Aging. 2013;8:1157–1165. PMID:24072964.
   PubMed Web of Science ®Google Scholar
• Kim J, Lee JK, Heo EY, Chung HS, Kim DK. The association of renin-angiotensin system blockades and pneumonia requiring admission in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:2159–2166. doi:10.2147/COPD.S104097. PMID:27672320.
   PubMed Web of Science ®Google Scholar
• Parikh MA, Aaron CP, Hoffman EA, Schwartz JE, Madrigano J, Austin JHM, Kalhan R, Lovasi G, Watson K, Stukovsky KH, et al. Angiotensin-Converting Inhibitors and Angiotensin II Receptor Blockers and Longitudinal Change in Percent Emphysema on Computed Tomography. The Multi-Ethnic Study of Atherosclerosis Lung Study. Ann Am Thorac Soc. 2017;14:649–658.
   PubMed Web of Science ®Google Scholar
• Ekström MP, Hermansson AB, Ström KE. Effects of cardiovascular drugs on mortality in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187:715–720. doi:10.1164/rccm.201208-1565OC. PMID:23328521.
   PubMed Web of Science ®Google Scholar
• Kanazawa H, Hirata K, Yoshikawa J. Effects of captopril administration on pulmonary haemodynamics and tissue oxygenation during exercise in ACE gene subtypes in patients with COPD: a preliminary study. Thorax. 2003;58:629–631. doi:10.1136/thorax.58.7.629. PMID:12832683.
   PubMed Web of Science ®Google Scholar
• Bertoli L, Lo Cicero S, Busnardo I, Rizzato G, Montanari G. Effects of captopril on hemodynamics and blood gasses in chronic obstructive lung disease with pulmonary hypertension. Respiration. 1986;49:251–256. doi:10.1159/000194887. PMID:3520734.
   PubMed Web of Science ®Google Scholar
• Ozyilmaz E, Kokturk N, Teksut G, Tatlicioglu T. Unsuspected risk factors of frequent exacerbations requiring hospital admission in chronic obstructive pulmonary disease. Int J Clin Pract. 2013;67:691–697. doi:10.1111/ijcp.12150. PMID:23758448.
   PubMed Web of Science ®Google Scholar
• Kon SS, Jolley CJ, Shrikrishna D, Montgomery HE, Skipworth JR, Puthucheary Z, Moxham J, Polkey MI, Man WD, Hopkinson NS. ACE and response to pulmonary rehabilitation in COPD: two observational studies. BMJ Open Respir Res. 2017;4:e000165. doi:10.1136/bmjresp-2016-000165. PMID:28321311.
   PubMed Web of Science ®Google Scholar
• Shrikrishna D, Tanner RJ, Lee JY, Natanek A, Lewis A, Murphy PB, Hart N, Moxham J, Montgomery HE, Kemp PR, et al. A randomized controlled trial of angiotensin-converting enzyme inhibition for skeletal muscle dysfunction in COPD. Chest. 2014;146:932–940. doi:10.1378/chest.13-2483. PMID:24556825.
   PubMed Web of Science ®Google Scholar
• Morrell N, Higham M, Phillips P, Shakur B, Robinson P, Beddoes R. Pilot study of losartan for pulmonary hypertension in chronic obstructive pulmonary disease. Respir Res. 2005;6:88. doi:10.1186/1465-9921-6-88. PMID:16060962.
   PubMed Web of Science ®Google Scholar
• Zielinski J, Hawrylkiewicz I, Gorecka D, Gluskowski J, Koscinska M. Captopril effects on pulmonary and systemic hemodynamics in chronic cor pulmonale. Chest. 1986;90:562–565. doi:10.1378/chest.90.4.562. PMID:3530649.
   PubMed Web of Science ®Google Scholar
• Andreas S, Herrmann-Lingen C, Raupach T, Luthje L, Fabricius JA, Hruska N, Körber W, Büchner B, Criée CP, Hasenfuss G, et al. Angiotensin II blockers in obstructive pulmonary disease:a randomised controlled trial. Eur Respir J. 2006;27:972–979. doi:10.1183/09031936.06.00098105. PMID:16446313.
   PubMed Web of Science ®Google Scholar
• Ptinopoulou AG, Pikilidou MI, Lasaridis AN. The effect of antihypertensive drugs on chronic kidney disease: a comprehensive review. Hypertens Res. 2013;36:91–101. doi:10.1038/hr.2012.157. PMID:23051659.
   PubMed Web of Science ®Google Scholar
• Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2005;4:CD003566.
   Google Scholar
• Ni Y, Shi G, Wan H. Use of cardioselective β-blockers in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized, placebo-controlled, blinded trials. J Int Med Res. 2012;40:2051–2065. doi:10.1177/030006051204000602. PMID:23321161.
   PubMed Web of Science ®Google Scholar
• Du Q, Sun Y, Ding N, Lu L, Chen Y. Beta-blockers reduced the risk of mortality and exacerbation in patients with COPD: a meta-analysis of observational studies. PLoS One. 2014;9:e113048. doi:10.1371/journal.pone.0113048. PMID:25427000.
   PubMed Web of Science ®Google Scholar